Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended)

NICE technology appraisals [TA161] Published date:

This guidance updates and replaces NICE technology appraisal 87 (published in January 2005).

Whether or not a postmenopausal woman who has had a bone fracture because of osteoporosis is offered treatment to prevent further fractures will depend on her age, her bone density and how many risk factors for fracture she has.

Alendronate is recommended as a possible treatment for preventing bone fractures in postmenopausal women who have already had a fracture and have had osteoporosis diagnosed.

If a woman can't take alendronate, risedronate and etidronate are recommended under certain circumstances as possible alternative treatments to prevent further fractures.

If a woman can't take alendronate or either risedronate or etidronate, then strontium ranelate and raloxifene are recommended under certain circumstances as possible alternative treatments to prevent further fractures.

If a woman can't take alendronate, or either risedronate or etidronate, or strontium ranelate, teriparatide is recommended under certain circumstances as a possible alternative treatment to prevent further fractures. Teriparatide is also recommended as a possible alternative treatment for a woman who has another fracture when she has been taking alendronate, risedronate or etidronate for 1 year (and her bone density has fallen).

The guidance says that women who are 75 or over may not need a bone scan to diagnose their osteoporosis.

  • Update 26 January 2011

    NICE has published updated final guidance on preventing osteoporotic fractures following a reconsideration of the use of strontium ranelate for the prevention and treatment of osteoporotic fragility fractures in postmenopausal women.

    In accordance with the Court of Appeal’s ruling on the technology appraisals of drugs for the prevention and treatment of osteoporotic fragility fractures in postmenopausal women, NICE asked the manufacturer of strontium ranelate to submit additional evidence. After having examined this additional evidence on strontium ranelate and an independent expert review of the evidence very carefully, the new independent Appraisal Committee reached the same conclusions as the original Appraisal Committee, and so the recommendations on strontium ranelate remain unchanged from those published originally. Consultees then had a chance to appeal against this decision but no appeals were received.

    NICE guidance on the use of alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the prevention and treatment of osteoporotic fragility fractures in postmenopausal women therefore remains unchanged.

  • Get involved